Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study

Gynecologic Oncology

Volumn 123, Issue 2, 2011, Pages 301-307

  Ferrero, Annamaria ^a   Dompè, Daniela ^a   Ravarino, Nicoletta ^a   Ramella, Angela ^a   Fuso, Luca ^a   Maggiorotto, Furio ^a   Tripodi, Elisa ^a   Zola, Paolo ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

Angiogenesis; Epitelian ovarian cancer; Molecular markers

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CA 125 ANTIGEN; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMOGLOBIN; PACLITAXEL; PROTEIN P53; TOPOTECAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EPITHELIAL OVARY CANCER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054725663     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.07.026     Document Type: Article

References (50)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A. Gadducci, S. Cosio, R. Tana, and A.R. Genazzani Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer Clin Rev Oncol/Hemat 69 2009 12 27
3. J. Folkman What is the evidence that tumours are angiogenetic dependent? J Natl Cancer Inst 82 1990 4 6
4. J. Folkman, and R. Kalluri Cancer without disease Nature 427 2004 787
5. M.E. Eichorn, A. Kleespies, and M.K. Angele Angiogenesis in cancer: molecular mechanisms clinical impact Langenbecks Arch Surg 392 2007 371 379
6. G. Berges, and L.E. Benjamin Tumorigenesis and the angiogenetic switch Nat Rev Cancer 3 2003 401 403
7. J.M. Rubatt, K.M. Darcy, and A. Hutson Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study Gynecol Oncol 112 2009 469 474
8. K.M. Darcy, W.E. Brady, and McBroom Associations between p53 expression and multiple measures of clinical outcome in high-risk, early stage or suptoptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study Gynecol Oncol 111 2008 487 495
9. D. Mukhopadhyay, L. Tsiokas, and V.P. Sukhatme Wild type p53 and v-Src opposing influences on human vascular endothelial growth factor gene expression Cancer Res 55 1995 6161 6165
10. M.J. Goodheart, M.A. Vasef, and A.K. Sood Ovarian cancer p53 mutation is associated with tumor microvessel density Gynecol Oncol 86 2002 85 90
11. R. Fujiwaki, K. Lida, and H. Kansaki Cyclooxygenase2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosporylase Hum Pathol 33 2002 213 219
12. R. Ali-Fehmi, M. Che, and I. Khalifeh The effect of ciclooxygenase-2 expression on tumor vascularity in advanced ovarian serous carcinoma Am Cancer Soc 98 2003 1423 1429
13. M. Sopel, I. Kasprzyk, and I. Berdowska Maspin and c-erbB2 expression in correlation with microvessel density in invasive ductal breast cancer Folia Histochem Cytobiol 43 2005 109 116
14. S.A. Eccles The role of c-erbB2/HER2/neu in breast cancer progression and metastasis J Mamm Gland Biol Neoplasia 6 2001 393 406
15. G. Ferrandina, F. Ranelletti, and L. Lauriola Cyclooxygenase2 (COX-2), epidermal growth factor receptor (EGFR) and Her-2/neu expression in ovarian cancer Gynecol Oncol 85 2002 305 310
16. T.A.H. Jarvinen, and E.T. Liu Effects of HER-2/neu on chemosensitivity of tumor cells Drug Resist Update 3 2000 319 324
17. J. Folkman A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular growth factor expression J Natl Cancer Inst 93 2001 734 735
18. C. Denkert, M. Kobel, and S. Pest Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma Am J Pathol 160 2002 893 903
19. A.A. Alvarez, J.R. Axelrod, and R.S. Whitaker Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients Gynecol Oncol 82 2001 273 278
20. J.S. Lee, J.D. Choi, and J.H. LEE Expression of cyclooxygenase-2n in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression Int J Gynecol Cancer 16 2006 247 253
21. K.D. Steffenson, M. Waldstroms, and E. Jakobsen The prognostic importance of ciclooxygenase 2 and HER2 expression in epithelial ovarian cancer Int J Gynecol Cancer 17 2007 798 807
22. A. Ferrero, P. Zola, and S. Mazzola Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer Gynecol Oncol 95 2004 323 329
23. N. Weidner Current Pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors Breast Cancer Res Treat 36 1995 169 180
24. P.B. Vermeullen, G. Gasparini, and S.B. Fox Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation Eur J Cancer 32 1996 2474 2484
25. P.J. van Diest, J.P. Zevering, L.C. Zevering, and J.P. Baak Prognostic value of microvessel quantitation in cisplatin treated FIGO 3 and 4 ovarian cancer patients Pathol Res Pract 191 1995 25 30
26. Y. Terai, M. Ueda, and K. Kumagai Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum Int J Gynecol Pathol 19 2000 354 360
27. K. Nakayama, A. Kanzaki, and Y. Takebayashi Different features of angiogenesis between ovarian and breast carcinoma Cancer Lett 170 2001 161 167
28. R. Ali-Fehmi, R.T. Morris, and S. Bandyopadhyay Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival Am J Obstet Gynecol 192 2005 819 825
29. H.C. Hollingsworth, E.C. Kohn, and S.M. Steinberg Tumor angiogenesis in advanced stage ovarian carcinoma Am J Pathol 147 1995 33 41
30. G. Gasparini, E. Bonoldi, and G. Viale Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas Int J Cancer 69 1996 205 211
31. A.A. Alvarez, H.R. Krigman, and R.S. Whitaker The prognostic significance of angiogenesis in epithelial ovarian carcinoma Clin Cancer Res 5 1999 587 591
32. A. Obermair, R. Wasicky, and A. Kaider Prognostic significance of tumor angiogenesis in epithelial ovarian cancer Cancer Lett 138 1999 175 182
33. M.R. Raspollini, G. Amunni, and A. Villanucci Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma Int J Gynecol Cancer 14 2004 815 823
34. M.J. Goodheart, J.M. Ritchie, and S.L. Rose The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer Clin Cancer Res 11 2005 3733 3742
35. J.K. Chan, A. Magistris, and V. Loizzi Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer Gynecol Oncol 99 2005 20 25
36. A. Gadducci, S. Cosio, and P. Zola Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable Anticancer Res 26 2006 3925 3932
37. A. Ferrero, N. Ravarino, and D. Dompè High microvessel density and low hemoglobin level as a prognostic factor for overall survival in advanced ovarian cancer Int J Gynecol Cancer 14 Suppl. 1 2004 9
38. P.J. Klemi, L. Pylkkanen, and P. Kiilholma p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma Cancer 76 1995 1201 1208
39. G. Ferrandina, A. Fagotti, and M.G. Salerno p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer Br J Cancer 81 1999 733 740
40. A. Protopapas, E. Diakomanolis, and A. Bamias The prognostic significance of the immunohistochemical expression of p53, bcl2, c-erbB2 and catepsin D in ovarian cancer patients receiving platinum with cyclofosphamide or paclitaxel therapy Eur J Gynecol Oncol 25 2004 225 229
41. Y.K. Lee, and N.H. Park Prognostic value and clinicopathological significance of p53 and PTEN in epithelial cancer Gynecol Oncol 112 2009 475 480
42. P. de Graeff, A.P. Crijns, and S. de Jong Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis Br J Cancer 101 2009 149 159
43. S.C. Rubin, C.L. Finstad, and G.Y. Wong Prevalence and significance of HER2 expression in advanced epithelial ovarian cancer: a multivariate analysis Am J Obstet Gynecol 168 1993 162 169
44. A. Fajac, J. Benard, and C. Lhomme C-erbB2 gene amplification and protein expression in ovarian epithelial tumor: evaluation of their respective prognostic significance by multivariate analysis Int J Cancer 64 1995 146 151
45. M.R. Raspollini, G. Amunni, and A. Villanucci HER2 neu and bcl2 in ovarian carcinoma, clinicopathologic, immunhistochemical and molecular study in patients with shorter and longer survival Appl Immunohistochem Mol Morphol 14 2006 181 186
46. P.P. Peethambaram, W.A. Cliby, and G. Lubiniecki Her2 expression in ovarian cancer: pre and post exposure to platinum chemotherapy Gynecol Oncol 9 2003 99 104
47. H. Meden, D. Marx, and T. Roegglen Overexpression of the oncogene c-erbB2 and response to chemotherapy in patients with ovarian cancer Int J Gynecol Pathol 17 1998 61 65
48. J.S. Ross, F. Yang, and B.V. Kallakury HER2 neu oncogene amplification by hybridation in epithelial tumors of the ovary Am J Clin Pathol 111 1999 311 316
49. F. Legge, A. Paglia, M. D'Asta, and G. Fuoco Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients BMC Cancer 11 2011 214
50. T. de La Motte Rouge, M.C. Petrella, and J. Michels New drugs and targeted therapeutic agents in ovarian cancer Bull Cancer 96 2009 1215 1224